Philip Charles Hoffman to Prognosis
This is a "connection" page, showing publications Philip Charles Hoffman has written about Prognosis.
Connection Strength
0.135
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
Score: 0.029
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
Score: 0.027
-
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2015 Dec 01; 33(34):4007-14.
Score: 0.019
-
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
Score: 0.015
-
Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83.
Score: 0.014
-
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol. 2008 Oct; 3(10):1159-65.
Score: 0.012
-
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
Score: 0.012
-
Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol. 1990 Aug; 8(8):1402-7.
Score: 0.003
-
Adenosquamous lung carcinoma: clinical characteristics, treatment, and prognosis. Ann Thorac Surg. 1987 Nov; 44(5):462-6.
Score: 0.003